The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-29 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
While von Grosse's claim that Fermi was actually producing protactinium (element 91) was quickly tested and disproved, Noddack's proposal that the uranium had been shattered into two or more much smaller fragments was simply ignored by most because existing nuclear theory did not include a way for this to be possible. Fermi and his team maintained that they were in fact synthesizing a new element, but the issue remained unresolved for several years. Although the many different and unknown radioactive half-lives in the experiment's results showed that several nuclear reactions were occurring, Fermi's group could not prove that element 93 was being produced unless they could isolate it chemically. They and many other scientists attempted to accomplish this, including Otto Hahn and Lise Meitner who were among the best radiochemists in the world at the time and supporters of Fermi's claim, but they all failed. Much later, it was determined that the main reason for this failure was because the predictions of element 93's chemical properties were based on a periodic table which lacked the actinide series. This arrangement placed protactinium below tantalum, uranium below tungsten, and further suggested that element 93, at that point referred to as eka-rhenium, should be similar to the group 7 elements, including manganese and rhenium.
== Combination with other antidiabetic drugs == A combination therapy of insulin and other antidiabetic drugs appears to be most beneficial in people who are diabetic, who still have residual insulin secretory capacity. A combination of insulin therapy and sulfonylurea is more effective than insulin alone in treating people with type 2 diabetes after secondary failure to oral drugs, leading to better glucose profiles or decreased insulin needs.
In October 2008, Anatoly Barankevich, the head of the Security Council of South Ossetia, said in an interview that during the war, "Firstly, they [the Georgians] had T-72 tanks, and we only have three tanks, and they are T-55, [...] We had moved them out secretly, put them near the city, and they did a good job, and then entered the city." Researcher Andrey Illarionov later commented on the remarks of Barankevich, "This means that the tanks were in the conflict zone. Near Tskhinvali, which is prohibited by the Dagomys Agreement." In November 2008, Novaya Gazeta reported that Valentin Malykh received a phone call from his son in Vladikavkaz on the early morning of August 7 and Valentin wanted to congratulate his son on his birthday. But his son said that he was being sent to the war in Tskhinvali.
== Prevention == Early and effective breastfeeding can minimize the likelihood of engorgement, latch difficulties, nipple trauma and bacterial infections. The surface of the nipple and breast pumps should be sterilized to remove sources of irritants before breastfeeding or pumping of milk. It may help prevent yeast infections and cross-contamination of bacteria between family members. Ideally, cleaning baby items and mothers' underwear like boiling or disinfecting pacifiers, diapers, bras and bathing equipment frequently can prevent infections. During breastfeeding, mothers should hold infants in the correct breastfeeding position in order to prevent nipple pain brought by poor positioning.
Sources: en.wikipedia.org
== Personal life == Sherman met and married Hildegard Schroeder while they were both graduate students at the University of Iowa, and they had three children: Karen, Marc, and Keith. In addition to his professional activities, he has participated in organizations such as the Boy Scouts of America, the Jewish War Veterans organization, and the Lions Club. Sherman died on December 1, 2023, at the age of 98.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
==== Deficit in consolidation of memory traces ==== α-CaMKII heterozygous mice express half the normal protein level as the wild-type level. These mice showed normal memory storage in the hippocampus, but deficits in consolidation of memory in the cortex.
=== Biological detection === The discovery of radiative recombination in aluminum gallium nitride (AlGaN) alloys by U.S. Army Research Laboratory (ARL) led to the conceptualization of UV light-emitting diodes (LEDs) to be incorporated in light-induced fluorescence sensors used for biological agent detection. In 2004, the Edgewood Chemical Biological Center (ECBC) initiated the effort to create a biological detector named TAC-BIO. The program capitalized on semiconductor UV optical sources (SUVOS) developed by the Defense Advanced Research Projects Agency (DARPA). UV-induced fluorescence is one of the most robust techniques used for rapid real-time detection of biological aerosols. The first UV sensors were lasers lacking in-field-use practicality. In order to address this, DARPA incorporated SUVOS technology to create a low-cost, small, lightweight, low-power device. The TAC-BIO detector's response time was one minute from when it sensed a biological agent. It was also demonstrated that the detector could be operated unattended indoors and outdoors for weeks at a time. Aerosolized biological particles fluoresce and scatter light under a UV light beam. Observed fluorescence is dependent on the applied wavelength and the biochemical fluorophores within the biological agent. UV induced fluorescence offers a rapid, accurate, efficient and logistically practical way for biological agent detection.
The common form of the inhibitory term also obscures the relationship between the inhibitor binding to the enzyme and its relationship to any other binding term, be it the Michaelis–Menten equation or a dose response curve associated with ligand receptor binding. To demonstrate the relationship the following rearrangement can be made:
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.